Mass General Cancer Center, Harvard Medical School
Boston, Massachusetts
Dr. Dejan Juric is the Director of the Termeer Center for Targeted Therapies and the Program Director of the Investigational Cancer Therapeutics Program at the Mass General Cancer Center. He is also the Principal Investigator within the Laboratory for Systems Pharmacology and the Harvard Program in Therapeutic Science. Primary focus of his research is drug development of novel targeted therapy agents for patients with breast cancer and other advanced solid tumors, including novel ER, PI3K and CDK inhibitors and their combinations. He has an extensive background in cancer biology and clinical and translational medicine, starting with the MD degree from the University of Zagreb, postdoctoral fellowship in cancer genomics, pharmacology and drug resistance at Stanford University and clinical training in internal medicine and medical oncology at the MGH. He is the coordinating principal investigator of numerous early drug development trials and he led the clinical development of alpelisib, culminating in SOLAR-1, resulting in the first FDA-approved precision oncology agent in PIK3CA-mutated breast cancer. In addition to the implementation and supervision of clinical trials, he directs serial biopsy and rapid autopsy programs at the Mass General Cancer Center, ultimately aimed at deeper understanding of therapeutic vulnerabilities of human tumors.
Disclosure information not submitted.
Wednesday, September 21, 2022
11:35 AM – 1:15 PM
Wednesday, September 21, 2022
12:30 PM – 12:40 PM
Wednesday, September 21, 2022
1:00 PM – 1:15 PM